The role of fulvestrant in endometrial cancer

Stefano Bogliolo, Chiara Cassani, Mattia Dominoni, Anna Orlandini, Simone Ferrero, Anna Daniela Iacobone, Franco Viazzo, Pierluigi Venturini, Arsenio Spinillo, Barbara Gardella

Research output: Contribution to journalArticle


INTRODUCTION: Endometrial cancer is the most common malignancy of the female genital tract in industrialized countries. The traditional treatment of endometrial cancer is based on a surgical approach. In recent years, systemic endocrine therapy has demonstrated good efficacy in recurrent or metastatic setting, delaying progression, ameliorating quality of life and palliating symptoms. Areas covered: Phase I and II studies on selective estrogen receptor down-regulators used for the treatment of endometrial cancer treatment have been reviewed. The pharmacokinetic and pharmacodynamic features of selective receptor down-regulators have been also investigated. Expert opinion: Selective estrogen receptor down-regulators may exhibit clinical efficacy in the treatment of gynecological malignancies due to their pure estrogen receptor antagonist properties. However, up to now data are still limited and some unsolved questions remain. Fulvestrant has poor oral bioavailability and low pharmacodynamic characteristics. Further trials are required to examine new selective estrogen receptor down-regulator agents with better pharmacodynamic and pharmacokinetic profiles.

Original languageEnglish
JournalExpert Opinion on Drug Metabolism and Toxicology
Publication statusE-pub ahead of print - Oct 4 2016


  • Journal Article

Fingerprint Dive into the research topics of 'The role of fulvestrant in endometrial cancer'. Together they form a unique fingerprint.

  • Cite this